Dose and schedule
RAPIDO
High-risk rectal cancer
High-risk rectal cancer
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Phase 1 | |||
| Short-course radiotherapy | 5 Gy × 5 fractions | One week | |
| Phase 2: 6 cycles | |||
| Oxaliplatin | 130 mg/m² | IV | Day 1 every 21 days |
| Capecitabine | 1000 mg/m² twice a day | Oral | Days 1 to 14 |
As in RAPIDO [1].
Evidence: RAPIDO (2021)
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Premedication and supportive care
- DPYD: consider testing before the fluoropyrimidine [2].
- Moderate antiemetics; avoid cold after oxaliplatin.
Monitoring and dose adjustment
- Pelvic MRI before and after treatment; blood counts before each cycle.
- Neuropathy; diarrhoea (radiotherapy and capecitabine).
Main evidence
Show detailsHide
Related cancer types
Treatment regimens (physicians)
References
2 referencesShow all references, 2 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/rapido-total-neoadjuvant-rectal/